Trial
NCT04022876
A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Aileron Therapeutics, Inc.
Collaborators
—
Condition
Non Small Cell Lung Cancer
Intervention
ALRN-6924
Why stopped
With a favorable safety profile the difference between treatment groups for the primary composite endpoint was not sufficient to generate statistically significant results with the targeted sample size
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-10-10